The first line therapy for CM patients carrying the BRAFV600E mutation (∼45% of all patients) consists of concurrent BRAFV600E/MEK inhibition or immunotherapy, to which resistance occurs. Here, MAP2K7 is linked to cutaneous mastocytosis.